Treatment of anal intraepithelial neoplasia and prevention of anal carcinoma

Thornhill J¹, Jit M², Klein K¹, Singh N³, Sheaff M³, Hicky N¹, Awosika D¹, Nathan M¹






NHS Trust

1. Homerton University Hospital **2. Health Protection Agency 3. Barts** Health NHS Trust

Demographics

Cohort characteristics	No of Patients (%)
AIN 2	56 (61.5%)
AIN3	35 (38.5%)
HIV +	56 (61.5%)
HIV -	33 (36.2%)
Male	82 (90.1%)
MSM	80 (87.9%)
Nadir CD4 <200	37 (66%)
Mean age	36.6








Background:


The rates of anal carcinoma (cancer) have increased over recent decades in Europe and the US^{1,2,3}. The anal cancer rates are much higher in HIV positive men and have increased over time⁴. Moreover, compared to HIV negative people, local clearance rate of anal cancer is much reduced in HIV positive people (87% v 38% at 5 years), after chemoradiotherapy⁵. Progression to anal cancer from high-grade anal intraepithelial neoplasia (AIN 2/3) has been noted in a number of small observational studies at a rate of 8.6% to 14.3% over 5 years^{6,7,8,9}. An opportunity may exist to prevent anal cancer through treatment of AIN 2/3. We present retrospective data on AIN 2/3 cases that underwent laser ablative treatment.

Methods:

Data on patients who had a minimum of 3 year follow-up after AIN 2/3 diagnosis and who underwent ablative treatment for AIN 2/3 was reviewed.



Pre-(1) and post-(2) laser treatment for high grade AIN disease



Results:

A total of 91 patients (35 AIN 3; 56 AIN 2) were identified. Fifty six (61.5%) were HIV positive.

Median follow-up for the cohort was 69 months (mean 69.9; range 36 – 180 months). None of the patients in this cohort developed anal cancer. Twenty five cases (45%) had been HIV + for 15 years or more.

Markov model-based analyses suggest that treatment may have prevented lesion progression in a proportion of patients.

One patient who did not meet the criteria of 3 years of follow-up and was thus excluded from the analysis went on to develop anal cancer. This 49 year old man was HIV + for 21 years with a CD4 nadir of 8. He had 3 quadrant AIN 3 disease.

Interpretation:

- In our cohort of 91 patients with high grade AIN disease, no one developed anal cancer after a median of 69 months of follow up (minimum 3 years). All patients received laser ablative treatment for AIN 2/3.
- Although no large natural history studies exist, available data suggests that AIN 2/3 in some instances can progress to anal cancer. Previously we established 36 months as an adequate period to assess outcome of treatment¹⁰.

- Though no one in this cohort developed cancer, there was a case of cancer in a treated patient (follow up <3 years). It is likely this represents a late presentation, where treatment had no impact in reversing the process of malignancy.
- We now need prospective data on treatments employed to prevent anal cancer. \bullet

References

- 1. Bower M, Powles T, Newsom-Davis T et al. (2004) HIV associated anal cancer. Has HAART reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 37: 1563-1565
- 2. Chaturvedi A, Madeleine MM, Biggar RJ et al. (2009) Risk of HPV-associated cancers among persons with AIDS. J Natl cancer Inst 101: 1120-1130
- 3. Patel P, Hanson DL, Sullivan PS et al. (2008) Incidence and types of cancer among HIV-infected persons compared with general population in the United States, 1992-2003. Ann Intern Med 148: 728-736
- 4. Crum-Cianflone N, Hullsiek K, Marconi V et al. (2010) Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 24: 535-543
- 5. Oehler-Janne C, Huguet F, Provencher S et al. (2008) HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A muticentric cohort study of HIV-positive patients receiving HAART. J Clin Oncol 26:2550-2557
- 6. Scholefield J, Castle M, Watson N. (2005) Malignant progression of high-grade anal intraepithelial neoplasia. Br J Surg 92: 1133-1136
- 7. Watson A, Smith B, Whitehead M et al. (2006) Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 76:715-717
- 8. Devaraj B, Cosman B. (2005) Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum 49: 36-40
- 9. Sobhani I, Walker F, Roudot-Thorval F et al. (2004) Anal carcinoma: incidence and effect of cumulative infections. AIDS 18: 1561-1569
- 10.Nathan M, Hickey N Mayuranathan L et al. (2008) Treatment of anal human papillomavirus-associated disease: A Long term outcome study. Int J STD AIDS 19:445-